• Firepower and growth gap report 2015

    Biopharma M&A reached record levels in 2014, with firms seeking focus, scale and growth. Read more about last year’s deal-making landscape in our 2015 outlook.

  • Navigating the payer landscape

    A revolution is happening in health care, and it’s being led by payers. Progressions, our global pharmaceutical report, explores how companies are responding.

  • Capital Confidence Barometer: Life Sciences

    Confidence in an improving global economy is decreasing for biotech and pharma executives. Find out more in our 11th Capital Confidence Barometer.

  • Firepower fireworks drive record biopharma M&A in 2014

    As the dust settled in the waning days of the year’s end, EY took stock of the biopharma deals consummated in 2014 to understand the implications for the year ahead.

  • The new revenue recognition standard - life sciences

    Due to the revenue recognition standards recently issued, life sciences entities may need to make changes. We highlight the key considerations and next steps.

  • IN VIVO magazine

    EY's Jeff Greene and Andrew Forman comment on deal activity in IN VIVO's September 2014 issue "M&A tops 2009 merger mania."

  • Commercial excellence in pharma 3.0

    The pharmaceutical industry is navigating a profound transformation into what we call “Pharma 3.0.” We explore how companies are adapting their commercial models in response.

  • Strategic divestments drive value

    Selling assets and re-shaping portfolios can help global companies navigate uncertainty, maximize growth opportunities and create value for their stakeholders. Learn how.

  • Final IRS regulations affect annual pharma fee

    Learn how final regulations issued by the IRS will change the way pharma manufacturers account for the annual branded prescription drug fee.

Life Sciences

Finding sustainability in biotechnology, pharmaceutical and medical technology

Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.

Our Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential.

We cover key issues in these areas:




Connect with us

Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.

EY - Deal Outlook 2015 webcast

You're invited - Deal Outlook 2015 webcast

Join us 11 February for an informative session on current deal drivers, market trends and a 2015 deal outlook for various sectors, including life sciences.